Oncotarget

Reviews:

Novel strategies to target the ubiquitin proteasome system in multiple myeloma

Susanne Lub, Ken Maes, Eline Menu, Elke De Bruyne, Karin Vanderkerken and Els Van Valckenborgh _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:6521-6537. https://doi.org/10.18632/oncotarget.6658

Metrics: PDF 2526 views  |   HTML 2223 views  |   ?  


Abstract

Susanne Lub1, Ken Maes1, Eline Menu1, Elke De Bruyne1, Karin Vanderkerken1 and Els Van Valckenborgh1

1 Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium

Correspondence to:

Els Van Valckenborgh, email:

Keywords: ubiquitin proteasome system, multiple myeloma

Received: September 11, 2015 Accepted: November 23, 2015 Published: December 18, 2015

Abstract

Multiple myeloma (MM) is a hematological malignancy characterized by the accumulation of plasma cells in the bone marrow (BM). The success of the proteasome inhibitor bortezomib in the treatment of MM highlights the importance of the ubiquitin proteasome system (UPS) in this particular cancer. Despite the prolonged survival of MM patients, a significant amount of patients relapse or become resistant to therapy. This underlines the importance of the development and investigation of novel targets to improve MM therapy. The UPS plays an important role in different cellular processes by targeted destruction of proteins. The ubiquitination process consists of enzymes that transfer ubiquitin to proteins targeting them for proteasomal degradation. An emerging and promising approach is to target more disease specific components of the UPS to reduce side effects and overcome resistance. In this review, we will focus on different components of the UPS such as the ubiquitin activating enzyme E1, the ubiquitin conjugating enzyme E2, the E3 ubiquitin ligases, the deubiquitinating enzymes (DUBs) and the proteasome. We will discuss their role in MM and the implications in drug discovery for the treatment of MM.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6658